LEX-WK-TPVQJN66crawled 2022-08-25 14:22Z
CMA Fines GlaxoSmithKline and Several Generic Companies £45 million for Delaying Market Entry of Generic Paroxetine in the UK
Inside EU Life Sciences · Inside EU Life Sciences · Published February 12, 2016
Work details
- author
- Inside EU Life Sciences
- firm or organization
- Covington & Burling LLP
- publication
- Inside EU Life Sciences
- practice area
- Antitrust, Competition and Trade
- published
- 2016-02-12
Citation
Inside EU Life Sciences, CMA Fines GlaxoSmithKline and Several Generic Companies £45 million for Delaying Market Entry of Generic Paroxetine in the UK, Inside EU Life Sciences (February 12, 2016) [The Library at LexBlog, LEX-WK-TPVQJN66, lexpid.org/TPVQJN66]